Edition:
United Kingdom

Achillion Reports Positive Interim Data For Ach-4471 Phase 2 Combination Trial With Eculizumab At The New Era Of Aplastic Anemia And Pnh Meeting


Friday, 17 May 2019 

May 17 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS POSITIVE INTERIM DATA FOR ACH-4471 PHASE 2 COMBINATION TRIAL WITH ECULIZUMAB AT THE NEW ERA OF APLASTIC ANEMIA AND PNH MEETING.ACHILLION - ACH-4471 INCREASED HEMOGLOBIN AND NEARLY ELIMINATED NEED FOR TRANSFUSIONS IN PATIENTS WITH PNH BEING TREATED WITH C5 INHIBITOR, ECULIZUMAB.ACHILLION PHARMACEUTICALS INC - ACH-4471 WAS GENERALLY WELL TOLERATED WHEN ADDED TO ECULIZUMAB IN PATIENTS WITH PNH.ACHILLION PHARMACEUTICALS - LOOK FORWARD TO COMPLETING PHASE 2 TRIAL THIS SUMMER & FUTURE DISCUSSIONS WITH REGULATORY AUTHORITIES.ACHILLION PHARMACEUTICALS INC - HOPE TO INITIATE A PHASE 3 PNH COMBINATION TRIAL OF ACH-4471 WITH C5 INHIBITORS IN FIRST HALF OF 2020. 

Company Quote

2.68
-0.04 -1.47%
26 Jun 2019